Know Cancer

forgot password

Prostate Cancer Utilities and Cost-Effectiveness Analysis

18 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Prostate Cancer Utilities and Cost-Effectiveness Analysis

The goal of this project is to incorporate patients' preferences into a previously developed
prostate cancer treatment decision-model and to understand the implications for doing so for
cost-effectiveness analysis. To do this, it is first necessary to obtain patient utility
scores (i.e., patient preference weights). To do this we will perform a survey of patients
visiting the urology clinic to undergo prostate biopsies to validate a method of utility
assessment, and understand the patients' individual evaluations of treatment-related health
studies. We will also ask patients questions relating to their anxiety levels concerning the
possible diagnosis of prostate cancer.

Inclusion Criteria:

- Patients undergoing prostate biopsy

Exclusion Criteria:

- Women and children will be excluded, as prostate cancer occurs in men only

- Diagnosis of dementia

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Utility scores for treatment outcomes

Outcome Description:

Patient utility scores (i.e. patient preference weights) are calculated using survery data will determine which prostate cancer treatment would be most cost-effective for each subject. Patients will be contacted by phone and patient records will be reviewed 90 days after the survey has been completed to determine whether this data reflects actual treatment decisions.

Outcome Time Frame:

90 days after enrollment

Safety Issue:


Principal Investigator

David Meltzer, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago


United States: Institutional Review Board

Study ID:




Start Date:

January 2004

Completion Date:

January 2015

Related Keywords:

  • Prostate Cancer
  • Prostate Cancer
  • Cost-Effectiveness Analysis
  • Utility Assessment
  • Prostatic Neoplasms



The University of Chicago Chicago, Illinois  60637